Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema

Area of Science:

• Ophthalmology
• Medical Research

Background:

• Diabetic maculopathy is a leading cause of vision loss in diabetic patients.
• Effective treatments are crucial for preserving visual function.

Observation:

• A prospective randomized clinical trial was conducted.
• 160 eyes of 92 patients with diffuse diabetic maculopathy were included.
• The study compared modified grid argon laser photocoagulation to an observation group.

Findings:

• Treated eyes showed significant visual acuity improvement at 12 and 24 months (P = 0.00007 and P = 0.00031).
• Observation eyes showed significant worsening of visual acuity at 12 and 24 months (P = 0.00007 and P = 0.0007).
• Systemic hypertension, vascular disease, cystoid macular edema, and initial visual acuity did not significantly alter prognosis.

Implications:

• Modified grid argon laser photocoagulation is an effective treatment for diffuse diabetic maculopathy.
• This intervention can halt or reverse vision decline in affected individuals.
• The procedure demonstrates a favorable risk-benefit profile for managing diabetic macular complications.